The II Brazilian Guidelines for the pharmacological treatment of patients hospitalized with COVID-19 Joint Guidelines of the Associação Brasileira de Medicina de Emergência, Associação de Medicina Intensiva Brasileira, Associação Médica Brasileira, Sociedade Brasileira de Angiologia e Cirurgia Vascular, Sociedade Brasileira de Infectologia, Sociedade Brasileira de Pneumologia e Tisiologia and Sociedade Brasileira de Reumatologia.
Maicon FalavignaCintia Laura Pereira de AraujoAlexandre Naime BarbosaKarlyse Claudino BelliVerônica ColpaniFelipe Dal PizzolRosemeri Maurici da SilvaLuciano César Pontes de AzevedoMaria Beatriz Souza DiasJosé Luiz Gomes do AmaralGilson Pires DornelesJuliana Carvalho FerreiraAna Paula da Rocha FreitasDébora Dalmas GräfHélio Penna GuimarãesSuzana Margareth Ajeje LoboFlávia Ribeiro MachadoMichelle Silva NunesMaura Salaroli de OliveiraSuena Medeiros ParahibaRegis Goulart RosaVania Cristina Canuto SantosMarcone Lima SobreiraViviane Cordeiro VeigaRicardo Machado XavierAlexandre Prehn ZavasckiCinara SteinCarlos Roberto Ribeiro de CarvalhoPublished in: Critical care science (2023)
New recommendations for the treatment of hospitalized patients with COVID-19 were generated, such as those for tocilizumab and baricitinib. Corticosteroids and prophylaxis for thromboembolism are still recommended, the latter with conditional recommendation. Several drugs were considered ineffective and should not be used to provide the best treatment according to the principles of evidence-based medicine and to promote resource economy.